We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Enhancement of Postocclusive Reactive Hyperaemia by Dipyridamole

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00268554
First Posted: December 22, 2005
Last Update Posted: March 28, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Radboud University
  Purpose
The purpose of this study is to determine whether dipyridamole enhances postocclusive reactive hyperaemia by increasing extracellular adenosine concentrations during ischemia and reperfusion. Furthermore we hypothesize that dipyridamole augments postocclusive reactive hyperaemia by increasing adenosine receptor stimulation.

Condition Intervention
Hyperemia Hypoxia Drug: dipyridamole Drug: caffeine

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Enhancement of Postocclusive Reactive Hyperaemia

Resource links provided by NLM:


Further study details as provided by Radboud University:

Primary Outcome Measures:
  • forearm blood flow

Estimated Enrollment: 12
Study Start Date: December 2005
Study Completion Date: July 2006
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • healthy volunteers between 18 and 50 years

Exclusion Criteria:

  • none specified
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00268554


Locations
Netherlands
Radboud university Nijmegen Medical Centre
Nijmegen, Gelderland, Netherlands, 6533 ZA
Sponsors and Collaborators
Radboud University
Investigators
Principal Investigator: Gerard Rongen, MD,PhD Radboud University
  More Information

ClinicalTrials.gov Identifier: NCT00268554     History of Changes
Other Study ID Numbers: PORH-dipy
First Submitted: December 21, 2005
First Posted: December 22, 2005
Last Update Posted: March 28, 2008
Last Verified: March 2008

Keywords provided by Radboud University:
adenosine
caffeine
dipyridamole

Additional relevant MeSH terms:
Hypoxia
Hyperemia
Signs and Symptoms, Respiratory
Signs and Symptoms
Vascular Diseases
Cardiovascular Diseases
Caffeine
Dipyridamole
Central Nervous System Stimulants
Physiological Effects of Drugs
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Purinergic P1 Receptor Antagonists
Purinergic Antagonists
Purinergic Agents
Neurotransmitter Agents
Platelet Aggregation Inhibitors
Vasodilator Agents